论文部分内容阅读
目的:利用Meta分析方法评价瑞舒伐他汀与阿托伐他汀在降脂同时对非糖尿病高脂血症患者血糖的影响.方法:检索PubMed、ISI Web of Knowledge、中国知网、万方数据、维普数据库中有关瑞舒伐他汀与阿托伐他汀治疗高脂血症患者的随机对照试验(RCT),文献检索年限为各数据库建库至2014年12月31日,对符合标准的RCT采用RevMan 5.2软件进行Meta分析.结果:共纳入4个RCT,累计484例非糖尿病高脂血症患者.Meta分析结果显示,与阿托伐他汀相比,瑞舒伐他汀对空腹血糖的影响差异无统计意义(MD=-1.02,95％ CI:-2.10 ～0.06,P=0.07),对糖化血红蛋白影响的差异有统计学意义(MD=-0.06,95％ CI:-0.10～-0.01,P=0.01).结论:现有证据表明瑞舒伐他汀对高脂血症患者的血糖影响可能会比阿托伐他汀更加稳定,但是这个差别较小.“,”Objective: To evaluate the effect of rosuvastatin on blood glucose compared with atorvastatin in patients with hyperlipidemia.Methods:Randomized controlled trials(RCTs)regarding rosuvastatin and atorvastatin treating hyperlipemia were searched in Medline, PubMed, ISI Web of Knowledge, CNKI, Wanfang Database and VIP.A Meta-analysis was conducted on the outcomes of the included trials with the assistance of RevMan 5.2 software.Results : Totally 4 RCT were discovered included 484 patients with hyperlipemia.Compared with atorvastatin, for rosuvastatin, there was no significant effect on fasting plasma glucose(MD =-1.02, 95％ CI:-2.10-0.06, P =0.07), while significant effect on HbA1c(MD =-0.06, 95 ％ CI:-0.10--0.01, P =0.01).Conclusion: Rosuvastatin had a more steady effect on blood glucose of patients with hyperlipemia than atorvastatin, but the difference was very small.